☆ 4.4 Article

Botulinum Toxin for Pediatric Migraine: A Retrospective Multisite Cohort Study

PEDIATRIC NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice

Lorenzo Cantarelli et al.

Summary: The study confirms the effectiveness and safety of drugs targeting the calcitonin gene-related peptide receptor (CGRPr) in real clinical practice for chronic migraine patients. However, there is little benefit from erenumab intensification compared to the standard dose, with similar effectiveness but worse tolerability.

ANNALS OF PHARMACOTHERAPY (2023)

Add to Collection

Article Anesthesiology

Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: a randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population

Shalini Shah et al.

Summary: This study found that subjects treated with OBTA reported a statistically significant decrease in migraine frequency, intensity, and Pediatric Migraine Disability Score compared with placebo at follow-up visits, but there was no significant difference in migraine duration between the two groups.

REGIONAL ANESTHESIA AND PAIN MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine

Scott W. Powers et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Clinical Neurology

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program

S. K. Aurora et al.

ACTA NEUROLOGICA SCANDINAVICA (2014)

Add to Collection

Review Clinical Neurology

OnabotulinumtoxinA in Pediatric Chronic Daily Headache

Marielle Kabbouche et al.

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)

Add to Collection

Article Clinical Neurology

Nonpharmacologic Treatment of Migraine With Low-Dose Propranolol or Amitriptyline

Tal Eidlitz-Markus et al.

PEDIATRIC NEUROLOGY (2012)

Add to Collection

Article Clinical Neurology

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

David W. Dodick et al.

HEADACHE (2010)

Add to Collection

Article Clinical Neurology

Experience With Botulinum Toxin Type A in Medically Intractable Pediatric Chronic Daily Headache

Karman Ahmed et al.

PEDIATRIC NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study

Ninan T. Mathew et al.

HEADACHE (2009)

Add to Collection

Article Clinical Neurology

Botox Treatment for Migraine and Chronic Daily Headache in Adolescents

Valerie W. Chan et al.

JOURNAL OF NEUROSCIENCE NURSING (2009)

Add to Collection

Article Pediatrics

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Topiramate for Migraine Prevention in Pediatric Subjects 12 to 17 Years of Age

Donald Lewis et al.

PEDIATRICS (2009)

Add to Collection

Article Anesthesiology

Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A

Moshe Jakubowski et al.

PAIN (2006)

Add to Collection

Article Clinical Neurology

Duration of migraine is a predictor for response to botulinum toxin type A

EJ Eross et al.

HEADACHE (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.